Logicor Announces Results for Year Ended 31 December 2018
Logicor announces strong financial performance for the year ended 31 December
- Net Operating Income (NOI): €639 million, which represents year on year growth of 2.5%, reflecting our strategic focus on increasing occupancy and capturing market rental growth. Over 60% of NOI is generated in the key markets of the UK (26%), Northern Europe1 (21%) and France (15%).
- Gross Asset Value: €12.5 billion, a 3.3% increase in valuation, which reflects the strong performance of our portfolio, in particular in Northern Europe.
- EPRA Occupancy: 94.4%, with physical occupancy up 70 bps over the year, underpinned by strong growth in each of our three largest regions of the UK (+120 bps), Northern Europe (+110 bps) and France (+220 bps).
- LTV: 51%, down from 52% at year end 2017 following increases in property values. At year end, our debt to EBITDA ratio was 11.3x.
In 2018 Logicor (rated BBB (Stable) by S&P) established a Euro Medium Term Note (‘EMTN’) programme and raised €1.8 billion of unsecured fixed-rate debt in the public capital markets alongside a €750 million unsecured Revolving Credit Facility (‘RCF’).
Through a combination of the bond proceeds, €300 million drawn under the RCF and €207 million of cash, Logicor repaid a portion of the secured, floating-rate facility, allowing us to move to a more flexible, diversified capital structure and increasing our weighted average maturity to 4.4 years.
Development and Expansion
In 2018 we invested €80 million in developing and expanding new logistics space for our customers, with four development projects completing in Italy, Finland, Germany and Romania with a total project cost of €74 million and an average yield on cost of 11%. We have eight further projects under way in Germany (4), Finland (2), UK (1) and Poland (1), with total projected costs of €79 million and a projected average yield on cost of 8%. All of these projects were 100% fully pre-leased before commencement.
Additionally, we have client-led development opportunities consisting of 18 projects that are primarily located in our core markets of Germany and France. These projects would deliver approximately 390,000 sqm of additional GLA with a total projected cost of €292 million.
Commenting on the results, Mo Barzegar, CEO & Chairman said:
“2018 was a great year for Logicor where we made excellent progress across a range of strategic initiatives including overall portfolio occupancy increases, capturing market rental growth and selective portfolio expansion based on strong customer demand.
With the high-quality of the assets that we own and operate and the continued excellence demonstrated by our customer-facing asset management teams across all of our markets, I am confident that the business is in excellent shape to continue to deliver strong performance in 2019.”
Simon Clinton, CFO added:
“Our successful debut capital markets issuance provides us with a more flexible and diversified capital structure and demonstrates strong investor support for our high-quality assets. Additionally, our strong operational results, which were driven by the combination of our deep customer relationships and well-located assets, exhibit our ability to generate stable cash flow.”
|EPRA Occupancy Rate||94.4%||n/a|
|GLA (million sqm)||13.6||13.5|
|GAV (€ million)||12,501||
|NOI (€ million)||639||n/a|
1 Northern Europe includes Austria, Belgium, Germany and Netherlands.
Logicor is the largest owner and operator of modern logistics and distribution properties in Europe. As at 31 December 2018 we own a portfolio of 621 high-quality properties with a lettable area of approximately 13.6 million square metres located in key European logistics markets. Logicor is headquartered in London and Luxembourg.
For further information please contact:
Simon Clinton, CFO
+44 (0) 207 198 4973
Courtney Huggins, Treasurer
+44 (0) 203 137 8412
Mark Roberts, Head of Communications
+44 (0) 207 198 2425
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Immersion Signs Agreement With TDK Electronics Bringing Haptics Design and Marketing to PowerHap Piezo Actuators24.4.2019 15:30:00 EEST | Tiedote
Immersion Corporation (NASDAQ:IMMR), the leading developer and licensor of touch feedback technology, announced that it has signed an agreement with TDK Corp. (TSE:6762) subsidiary TDK Electronics for the design and marketing of haptic feedback for TDK PowerHap™ piezo actuators. Under the agreement, Immersion will include TDK’s actuators in reference designs for automotive, industrial and other markets. Immersion will also certify the components for use with its software products. This will enable TDK’s customers in a wide variety of markets to rapidly implement cutting-edge haptic solutions with its high-performance actuators. With 25 years in the field of touch technology, Immersion brings together the art of design and the precise science behind haptic feedback in actuators and ICs. The company connects the haptic ecosystem through the certification of haptic components, helping partners like TDK and their customers maintain consistency and high-fidelity haptic experiences across de
Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities24.4.2019 15:30:00 EEST | Tiedote
Kite, a Gilead Company (Nasdaq: GILD), today announced plans for a new facility in Frederick County, Maryland, which will produce innovative cell therapies for people with cancer. The 20-acre site will significantly expand Kite’s ability to manufacture a variety of chimeric antigen receptor T (CAR T) therapies, including Yescarta® (axicabtagene ciloleucel), Kite’s first commercially available CAR T cancer therapy, and investigational T cell receptor (TCR) cell therapies being evaluated in solid tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005257/en/ “This new facility in Frederick County builds on our substantial technical capabilities and rapid progress in making personalized CAR T and TCR cell therapies for people with cancer. As we advance our industry-leading cell therapy pipeline and seek to help a growing number of people with cancer, expanding and investing in our manufacturing capabilities is essentia
SugarCRM Announces Game-Changing Product Enhancements to Accelerate Growth, Improve Business Performance and Deliver Exceptional Customer Experiences24.4.2019 15:00:00 EEST | Tiedote
SugarCRM Inc.®, the company that helps organizations build better business relationships, today announced several new platform capabilities to help companies to accelerate their business growth. These new capabilities will enable them to resolve customer issues quickly, collaborate more effectively, make faster and more informed decisions about their customers, eliminate time-consuming manual processes, expand real-time mobile access to critical customer information – and do all of this on the new, blazing-fast Sugar 9 platform. “With these significant enhancements, our customers can now collaborate and communicate more effectively, know more about their customers to quickly make better decisions and confidently transact more business with faster quotes, more automation and rock-solid SOC 2 compliance. Most importantly, we have boosted system performance to new heights, enabling customers to process up to 70% more transactions without investing in new hardware,” says Rich Green, chief
USD$90 Million Initiative between A*Star, Aptorum Group and Aeneas Capital to Drive Healthcare Innovations24.4.2019 15:00:00 EEST | Tiedote
Aptorum Group Limited (Nasdaq: APM), Aeneas Capital Limited, and A*ccelerate Technologies Pte Ltd, the enterprise office of the Agency for Science, Technology and Research (A*STAR), have signed a USD$90 million agreement to co-create local deep tech start-ups in the healthcare and life sciences sector. This agreement, is the latest in a series of venture co-creation (VCC) agreements signed by A*ccelerate to strengthen the start-up ecosystem in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005535/en/ (Photo: Business Wire) Through this agreement, Aptorum Group and A*ccelerate are looking at creating up to 20 deep tech ventures in Singapore over the next five years. These enterprises will leverage technologies co-developed by A*STAR research institutes and Aptorum Group. As part of this agreement, the parties involved will also support the start-ups’ growth through actively nurturing the entrepreneurs. This w
IONITY Fast Charging Network Relies on has·to·be Know-How for the Long Term24.4.2019 13:18:00 EEST | Tiedote
The IONITY joint venture aims to help electromobility achieve a breakthrough in Europe with a nationwide network of super-fast charging stations. The Austrian electromobility provider, has·to·be, is playing an important role in this. The red-white-red company will take care of the reliable and trouble-free operation of the charging stations. The two companies have agreed on a long-term cooperation so that the expansion of the Europe-wide network can proceed according to plan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424005465/en/ has·to·be and IONITY focus on long-term cooperation (Graphic: Business Wire) has·to·be, based in Radstadt (Salzburg), specializes in smart solutions for e-charging stations. For this purpose, the company has developed intelligent software for the management of electrical charging infrastructures. The product is called be.ENERGISED and is used successfully at more than 14,000 charging statio
Knopp Biosciences Receives FDA Orphan Drug Designation for Dexpramipexole for Treatment of Hypereosinophilic Syndrome24.4.2019 13:00:00 EEST | Tiedote
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases with high unmet needs, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation to dexpramipexole, its oral drug candidate for the treatment of hypereosinophilic syndrome (HES). HES is a rare and often incapacitating disorder with limited treatment options. The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose, or prevent diseases and disorders that affect fewer than 200,000 people in the U.S. This designation provides for a seven-year marketing exclusivity period against competition, as well as certain incentives, including federal grants, tax credits and a waiver of PDUFA filing fees. “We are very pleased to receive orphan drug designation for dexpramipexole for HES,” said Michael Bozik, M.D., CEO of Knopp Biosc
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme